HanAll Biopharma clarified that the new FcRn inhibitor HL161ANS (IMVT-1402), unveiled by its licensed partner Immunovant as a new development program, is a compound discovered and developed by HanAll. Both batoclimab and HL161ANS compounds were licensed to Roivant Sciences in regions including North America, South America, and Europe in 2017. HL161ANS demonstrated deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein in animal studies.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
36,950 KRW | -0.94% | +10.13% | -16.59% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-16.59% | 1.38B | |
+34.35% | 705B | |
+31.01% | 583B | |
-3.49% | 364B | |
+20.15% | 332B | |
+6.19% | 291B | |
+15.08% | 238B | |
-3.44% | 210B | |
+10.03% | 209B | |
+9.21% | 169B |
- Stock Market
- Equities
- A009420 Stock
- News Hanall Biopharma Co., Ltd.
- Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner